All In Biotech

Drug Trial Radar · NCT07620366

To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Liver Fibrosis

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jun 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial to evaluate efficacy and safety of QL2401 in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis (F2-F3).

Conditions

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions

  • QL2401 25 mgDrug

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 25 mg, once-weekly for 48 weeks.

  • QL2401 50 mgDrug

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 50 mg, once-weekly for 48 weeks.

  • QL2401 100 mgDrug

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive QL2401 100 mg, once-weekly for 48 weeks.

  • QL2401 placebo 25 mgDrug

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

  • QL2401 placebo 50 mgDrug

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

  • QL2401 placebo 100 mgDrug

    Matching placebo administered via subcutaneous injection, once-weekly for 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in liver fat content (%) measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 12 relative to baselineTime frame: Baseline to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.